Cancer Diagnosis Services For Medical Specialties
-
Manufactured by Soteria Medical BVbased in NETHERLANDS
Prostate cancer is the most common cancer, other than non-melanoma skin cancer, and the second leading cause of cancer-related death in men in the United States. Prostate cancer incidence rates rose dramatically in the late 1980s, when screening with the prostate-specific antigen (PSA) test, which received initial U.S. Food and Drug Administration approval in 1986, came into wide use. It is ...
-
based in CHINA
Cancer is a complicated disease caused by genetic variation. The genetic variation may deprive cells of the normal control function, leading to immortalization and cancer. And targeted drugs work well in cancer therapy, which can kill cancer cells that carry specific genes of variation. However, patients may differ from each other regarding the in vivo genetic variation. As a result, patients ...
-
by SoBran Inc.based in USA
Our scientific and technical experts assemble customized research programs with attention to your specific project requirements, timelines and budget. To support small animal preclinical toxicology and drug discovery, we offer an expanding range of services that meet GLP and non-GLP compliant in vivo research requirements. Program management is certified to the ISO 9001:2008 standard. ...
-
Manufactured by Data Driven Diagnostic Sciences (D3Sciences)based in USA
Detecting, Diagnosing and Treating Cancer: To detect, diagnose, and treat internal cancer requires a team of healthcare providers led generally by three specialist physicians: oncologists, radiologists, and pathologists. Upon examining a patient, and assessing the indicators for the presence of the disease, the oncologist consults with the radiologist and the decision is made for the radiologist ...
-
Manufactured by Grail, Inc.based in USA
Evaluation of a New Blood Test for Detecting Multiple Types of Cancer Early. The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom. It is designed to enroll approximately 25,000 men and women age 50 to 77 years who do not have a cancer diagnosis at the time of enrollment. SUMMIT aims to further evaluate GRAIL’s blood ...
-
based in USA
Our sub-specialized pathology services provide expertise in the areas of breast, gynecologic, gastrointestinal, molecular, and urology ...
-
based in INDIA
Cancer diagnostics at iGenetic covers the entire ...
-
based in USA
Cytogenetics is the study of normal and abnormal chromosomes in relation to disease. Sometimes called chromosome analysis or karyotyping, cytogenetic tests are used to gain diagnostic and prognostic insights regarding solid tumor cancers and hematologic malignancies, which can be the result of chromosome rearrangements or altered chromosome number (ploidy). Our cytogenetic tests include a ...
-
Manufactured by Bracco Spabased in ITALY
The Centro Diagnostico Italiano is a polyclinic based in Milan. With 24 satellite units in the city and in Lombardy, CDI offers different services of prevention, diagnosis, rehabilitation and personalized treatment, with a focus on radio-surgery and on ...
-
Manufactured by Ulisse BioMedbased in ITALY
Ulisse BioMed proposes a specific offer for the detection and genotyping of Human Papillomavirus (HPV) to physicians and professionals in the gynecological ...
-
by Biocollectbased in POLAND
We offer tools and devices for cervical cancer detection and diagnostic including a self-sampling device of our partner Oasis Diagnostics® Corporation for cervico-vaginal specimen for HPV test as well as for testing other viruses and bacteria from STI ...
-
based in CANADA
While tissue samples are the standard for cancer molecular profiling, tissue can often be challenging to obtain. Surgical biopsy may be risky or impossible, the biopsy procedure may have resulted in insufficient or exhausted tissue, or the sample acquired resulted in poor quality DNA. Whatever the reason, plasma assays can provide a less invasive alternative or complement to tissue assays. Plasma ...
-
based in CANADA
Find It focuses on gene mutations that can be addressed by current FDA-approved therapies. Find It is more than an assay: it’s a complete solution. Canexia Health partners leverage our expert end-to-end support and proprietary technology as well as a focused panel that identifies therapeutic targets for patients, acquired drug resistance mutations, and mutations with prognostic and ...
-
Manufactured by RareStone Groupbased in CHINA
In recent years, the incidence of childhood cancer has been on the rise, and malignant tumor has become one of the main causes of death among adolescents. More than 250,000 children worldwide are diagnosed with cancer each year, and about 90,000 children die of cancer—making it the leading cause of death among children. In addition to leukemia, malignant lymphoma and other blood tumors, ...
-
Manufactured by MiraDxbased in USA
Independent of their BRCA1/BRCA2 mutational status, ...
-
Manufactured by Biomatik Corporationbased in CANADA
Biomatik has been proudly serving 10,000+ scientists since 2002. If you cannot find a protein from our extensive protein catalog to suit your research needs, then our custom protein production service team can help. Our custom protein production service utilizes our proprietary codon optimization algorithm and in-house gene synthesis technology to offer customers the best customized research ...
-
Manufactured by Grail, Inc.based in USA
Mapping the Landscape of Genomic Cancer Signals in the Blood. The Circulating Cell-free Genome Atlas (CCGA) Study is a prospective, observational, longitudinal, study designed to characterize the landscape of genomic cancer signals in the blood of people with and without cancer. The study has enrolled approximately 15,000 participants across 142 sites in the United States and Canada, and includes ...
-
Manufactured by Grail, Inc.based in USA
Development of a Blood Test with Prospective Study Cohort of 100,000 Participants. The STRIVE Study is a prospective, observational, longitudinal, cohort study that has enrolled approximately 100,000 women at the time of their screening mammogram. A subset of the data from STRIVE will be used to help validate GRAIL’s blood test for the early detection of multiple cancer types. Participants ...
-
Manufactured by ImCare Biotech, LLCbased in USA
Overexpression of a novel apoptosis inhibitor, serine protease inhibitor Kazal (SPIK), has been demonstrated in HCC and other cancer patients. In addition, high levels of SPIK are closely associated with early recurrence in cancer patients following surgical resection. Because recurrence of cancer often implies the immune system’s inability to clear lingering oncogenic cells, early cancer ...
-
based in USA
This year alone, oral cancer, including oral cancer, will affect the lives of hundreds of thousands of individuals and their families. ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you